280 related articles for article (PubMed ID: 12843230)
21. Patient-specific scaling of reference S-values for cross-organ radionuclide S-values: what is appropriate?
Petoussi-Henss N; Bolch WE; Zankl M; Sgouros G; Wessels B
Radiat Prot Dosimetry; 2007; 127(1-4):192-6. PubMed ID: 17569687
[TBL] [Abstract][Full Text] [Related]
22. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.
Barone R; Borson-Chazot F; Valkema R; Walrand S; Chauvin F; Gogou L; Kvols LK; Krenning EP; Jamar F; Pauwels S
J Nucl Med; 2005 Jan; 46 Suppl 1():99S-106S. PubMed ID: 15653658
[TBL] [Abstract][Full Text] [Related]
23. Paired-organ and other selected absorbed fraction for the Korean Reference Adult Male model.
Kim JH; Whang JH; Kim CS
Radiat Prot Dosimetry; 2006; 118(4):395-401. PubMed ID: 16357027
[TBL] [Abstract][Full Text] [Related]
24. Considerations of marrow cellularity in 3-dimensional dosimetric models of the trabecular skeleton.
Bolch WE; Patton PW; Rajon DA; Shah AP; Jokisch DW; Inglis BA
J Nucl Med; 2002 Jan; 43(1):97-108. PubMed ID: 11801712
[TBL] [Abstract][Full Text] [Related]
25. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy.
Konijnenberg M; Melis M; Valkema R; Krenning E; de Jong M
J Nucl Med; 2007 Jan; 48(1):134-42. PubMed ID: 17204710
[TBL] [Abstract][Full Text] [Related]
26. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
Shen S; Forero A; LoBuglio AF; Breitz H; Khazaeli MB; Fisher DR; Wang W; Meredith RF
J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
[TBL] [Abstract][Full Text] [Related]
27. MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions--radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee.
Bolch WE; Bouchet LG; Robertson JS; Wessels BW; Siegel JA; Howell RW; Erdi AK; Aydogan B; Costes S; Watson EE; Brill AB; Charkes ND; Fisher DR; Hays MT; Thomas SR
J Nucl Med; 1999 Jan; 40(1):11S-36S. PubMed ID: 9935083
[TBL] [Abstract][Full Text] [Related]
28. Biodistribution and radiation dosimetry of the dopamine D2 ligand 11C-raclopride determined from human whole-body PET.
Slifstein M; Hwang DR; Martinez D; Ekelund J; Huang Y; Hackett E; Abi-Dargham A; Laruelle M
J Nucl Med; 2006 Feb; 47(2):313-9. PubMed ID: 16455638
[TBL] [Abstract][Full Text] [Related]
29. Primary radiation dosimetry of a novel PET radiopharmaceutical
Cheki M; Gali H
Hell J Nucl Med; 2017; 20(3):241-246. PubMed ID: 29177263
[TBL] [Abstract][Full Text] [Related]
30. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates.
Siegel JA; Thomas SR; Stubbs JB; Stabin MG; Hays MT; Koral KF; Robertson JS; Howell RW; Wessels BW; Fisher DR; Weber DA; Brill AB
J Nucl Med; 1999 Feb; 40(2):37S-61S. PubMed ID: 10025848
[TBL] [Abstract][Full Text] [Related]
31. MIRD Pamphlet No. 14 revised: A dynamic urinary bladder model for radiation dose calculations. Task Group of the MIRD Committee, Society of Nuclear Medicine.
Thomas SR; Stabin MG; Chen CT; Samaratunga RC
J Nucl Med; 1999 Apr; 40(4):102S-123S. PubMed ID: 10210232
[TBL] [Abstract][Full Text] [Related]
32. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.
Elgqvist J; Bernhardt P; Hultborn R; Jensen H; Karlsson B; Lindegren S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Mar; 46(3):464-71. PubMed ID: 15750160
[TBL] [Abstract][Full Text] [Related]
33. Normal organ radiation dosimetry and associated uncertainties in nuclear medicine, with emphasis on iodine-131.
Brill AB; Stabin M; Bouville A; Ron E
Radiat Res; 2006 Jul; 166(1 Pt 2):128-40. PubMed ID: 16808602
[TBL] [Abstract][Full Text] [Related]
34. A new rectal model for dosimetry applications.
Mardirossian G; Tagesson M; Blanco P; Bouchet LG; Stabin M; Yoriyaz H; Baza S; Ljungberg M; Strand SE; Brill AB
J Nucl Med; 1999 Sep; 40(9):1524-31. PubMed ID: 10492375
[TBL] [Abstract][Full Text] [Related]
35. MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature.
Bolch WE; Eckerman KF; Sgouros G; Thomas SR
J Nucl Med; 2009 Mar; 50(3):477-84. PubMed ID: 19258258
[TBL] [Abstract][Full Text] [Related]
36. A revised dosimetric model of the adult head and brain.
Bouchet LG; Bolch WE; Weber DA; Atkins HL; Poston JW
J Nucl Med; 1996 Jul; 37(7):1226-36. PubMed ID: 8965203
[TBL] [Abstract][Full Text] [Related]
37. Absolute organ activity estimated by five different methods of background correction.
Buijs WC; Siegel JA; Boerman OC; Corstens FH
J Nucl Med; 1998 Dec; 39(12):2167-72. PubMed ID: 9867163
[TBL] [Abstract][Full Text] [Related]
38. Development of a voxel phantom of Japanese adult male in upright posture.
Sato K; Noguchi H; Endo A; Emoto Y; Koga S; Saito K
Radiat Prot Dosimetry; 2007; 127(1-4):205-8. PubMed ID: 17553860
[TBL] [Abstract][Full Text] [Related]
39. S-factor calculations for mouse models using Monte-Carlo simulations.
Bitar A; Lisbona A; Bardiès M
Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):343-51. PubMed ID: 17538523
[TBL] [Abstract][Full Text] [Related]
40. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
